title: Apremilast, albiglutide, and empagliflozin.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
authors.forename: Stephanie
authors.initials: S
authors.lastname: Yenner
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005960:Glucosides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D013792:Thalidomide; C534611:rGLP-1 protein; D052216:Glucagon-Like Peptide 1; C570240:empagliflozin; C505730:apremilast